# Impact of Long-Term Cannabidiol (CBD) Treatment on Mouse Kidney Transcriptome
## 3 Results
\begin{table}
\begin{tabular}{l l l l l l l} \hline \hline \multicolumn{1}{c}{} & \multicolumn{4}{c}{**10 mg CBD vs. Control**} & \multicolumn{2}{c}{**20 mg CBD vs. Control**} \\ \hline
**Symbol** & **Ensembl ID** & **Description** & **log2 FC * & **FDR ** & **log2 FC** & **FDR ** \\ \hline Dbp & ENSMUSG00000059824 & D site albumin promoter binding protein & 2.75 & \(9.29\times 10^{-34}\) & 3.36 & \(4.79\times 10^{-52}\) \\ \hline Ppard & ENSMUSG00000002250 & peroxisome proliferatorator activator receptor delta & \(-0.98\) & \(3.11\times 10^{-10}\) & \(-1.03\) & \(1.30\times 10^{-11}\) \\ \hline Per3 & ENSMUSG00000028957 & period circadian clock 3 & \(1.08\) & \(1.93\times 10^{-7}\) & 1.39 & \(1.09\times 10^{-13}\) \\ \hline Nps2 & ENSMUSG00000026077 & neuronal PAS domain protein 2 & \(-1.42\) & \(1.67\times 10^{-5}\) & \(-1.45\) & \(4.00\times 10^{-6}\) \\ \hline Ppm1h & ENSMUSG00000034613 & protein phosphatase 1H (PP2C domain containing) & \(-0.55\) & \(8.22\times 10^{-5}\) & \(-0.56\) & \(1.63\times 10^{-5}\) \\ \hline Ypel2 & ENSMUSG00000018427 & yipipee like 2 & \(-1.01\) & \(1.00\times 10^{-4}\) & \(-1.35\) & \(8.63\times 10^{-10}\) \\ \hline Acmsd & ENSMUSG00000026348 & amino carboxymuconate semialdehyde decarboxylase & \(-0.76\) & \(1.05\times 10^{-3}\) & \(-0.91\) & \(3.50\times 10^{-6}\) \\ \hline Rorc & ENSMUSG00000028150 & RAR-related orphan receptor \(\gamma\) & \(-0.68\) & \(1.05\times 10^{-3}\) & \(-0.57\) & \(7.06\times 10^{-3}\) \\ \hline Nfli3 & ENSMUSG00000056749 & nuclear factor. interleukin 3, regulated & \(-0.98\) & \(2.06\times 10^{-3}\) & \(-1.31\) & \(6.30\times 10^{-7}\) \\ \hline Cyp2a5 & ENSMUSG00000005547 & cytochrome P450, family 2, subfamily a, polypeptide 5 & 1.42 & \(4.59\times 10^{-8}\) & \(1.42\) & \(4.59\times 10^{-8}\) \\ \hline Bhlhe41 & ENSMUSG00000030256 & basic helix-loop-helix family, member e41 & 1.46 & \(1.45\times 10^{-6}\) & \(1.46\) & \(1.45\times 10^{-6}\) \\ \hline  & ENSMUSG00000120875 & novel transcript & 1.25 & \(1.75\times 10^{-6}\) & 1.25 & \(1.75\times 10^{-6}\) \\ \hline  & \multicolumn{4}{l}{* log2 fold change in expression level; ** \(p\)-value of the Wald test (DeSeq2) for differential expression, corrected for multiple testing using the FDR method.} \\ \end{tabular}
\end{table} 
Table 1: The most significantly altered genes with both CBD treatments (top 12). \begin{table}
\begin{tabular}{l c c c c} \hline \hline \multicolumn{1}{c}{**Biological Process**} & \multicolumn{1}{c}{**CBD Dose (mg/kg b.w.)**} & \multicolumn{1}{c}{**Gene Regulation**} & \multicolumn{1}{c}{**FDR *} & \multicolumn{1}{c}{**Enrichment **} \\ \hline Response to stimulus & \(10\) & Up & \(0.049\) & \(72\) \\ \hline Circadian rhythm & \(10\) & Up & \(0.049\) & \(23.1\) \\ \hline Circadian behavior & \(10\) & Up & \(0.049\) & \(76.2\) \\ \hline Nutrient response & \(10\) & Down & \(0.025\) & \(17.5\) \\ \hline Response to redox states & \(10\) & Down & \(0.025\) & \(157.8\) \\ \hline Negative regulation of the glucocorticoid receptor signaling pathway & \(10\) & Down & \(0.031\) & \(210.4\) \\ \hline Diurnal regulation of gene expression & \(10\) & Down & \(0.031\) & \(32.7\) \\ \hline Intracellular receptor signaling pathway & \(10\) & Down & \(0.031\) & \(12.4\) \\ \hline Glucocorticoid receptor signaling pathway & \(10\) & Down & \(0.031\) & \(114.8\) \\ \hline Corticosteroid receptor signaling pathway & \(10\) & Down & \(0.031\) & \(78.9\) \\ \hline Physiological rhythm & \(20\) & Up & \(0.026\) & \(6.4\) \\ \hline Response to the stimulus & \(20\) & Up & \(0.025\) & \(19.3\) \\ \hline Circadian rhythm & \(20\) & Up & \(0.025\) & \(20.4\) \\ \hline Metabolism process of arachidonic acid & \(20\) & Up & \(0.047\) & \(17.8\) \\ \hline \hline \end{tabular}
\end{table} 
Table 2: List of top GO biological processes (FDR < 0.05) overrepresented by genes altered through both CBD treatments.